Enanta Pharmaceuticals (ENTA) Gains from Investment Securities (2012 - 2026)

Enanta Pharmaceuticals has reported Gains from Investment Securities for 15 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 2728.89% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 2728.89% YoY), and the FY2025 full-year result was $5.8 million, up 11.09% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $1.3 million, down from $6.6 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $6.6 million in Q4 2025, with the low at -$23.7 million in Q3 2024.
• Historically, Gains from Investment Securities has averaged -$572066.7 across 5 years, with a median of $477000.0 in 2024.
• Annual changes were most pronounced in 2024 — Gains from Investment Securities sank 581.95% — and 2026, when it surged 2728.89%.
• Enanta Pharmaceuticals' Gains from Investment Securities stood at $825000.0 in 2022, then sank by 520.97% to -$3.5 million in 2023, then slumped by 581.95% to -$23.7 million in 2024, then soared by 128.05% to $6.6 million in 2025, then plunged by 80.84% to $1.3 million in 2026.
• The last three Gains from Investment Securities figures came in at $1.3 million (Q1 2026), $6.6 million (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.